Simultaneous detection of genetic and immunological markers in non-small cell lung cancer: prediction of metastatic potential of tumor.
The restriction fragment length polymorphism of c-Ha-ras-1 and L-myc genes and expression of cell surface effector molecules were studied to determine their potential utility as markers for assessing risk of metastasis in 84 lung cancer patients. We performed a comparative study of primary lung carcinomas, metastases, adjacent tissues and blood samples in a group of patients with lung cancer of different histological types, grade of differentiation and presence of regional and distant metastasis. No differences in the frequency of c-Ha-ras-1 rare alleles were found between lung cancer patients and unaffected controls. The detection of common a4-allele seems to be associated with metastasis and low differentiation of lung carcinomas. S-allele of L-myc was observed in 82.6% of patients with metastatic lesions. Homozygosity of L-allele patients was not evidence for distant metastasis and only 17.4% of these patients have metastatic lesions of the lymph nodes. The expression of HLA class I and receptor of transferrin (TrRec) were tested immunohistochemically in the same patients. In the group of squamous cell carcinomas with regional metastases the expression of HLA class I antigens was decreased [7/21 (33.3%) positive staining tumors versus 13/20 (65.0%) in the group without metastases]. The opposite situation was observed for TrRec. The data of restriction fragment length polymorphism of oncogenes and expression of two cell surface effector molecules, identified in the same patients, were combined. The registration of more than one poor marker, tested in individuals with squamous cell carcinoma, closely correlated with dissemination and advanced stage of the disease. Nearly 90% (20/22) of patients with well and moderately differentiated tumor revealed metastatic lesions versus 6.6% (1/15) of patients with manifestation of a single poor marker. Finally, proposals could be made for the development of a risk group that incorporates both clinical and molecular biology features in the prediction of metastasis.
Zborovskaya
I
I
Blokhin's Cancer Research Center of Medical Science Academy, Moscow, Russia.
Gasparian
A
A
Kitaeva
M
M
Polotzky
B
B
Tupitzin
N
N
Machaladze
Z
Z
Gerasimov
S
S
Shtutman
M
M
Jakubovskaya
M
M
Davidov
M
M
Tatosyan
A
A
D000230:Adenocarcinoma / Q000235:genetics* / Q000276:immunology* / Q000556:secondary; D000483:Alleles; D015703:Antigens, CD / Q000032:analysis*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000276:immunology* / Q000556:secondary; D005260:Female; D016259:Genes, myc / Q000235:genetics*; D011905:Genes, ras / Q000235:genetics*; D005819:Genetic Markers; D005838:Genotype; D015395:Histocompatibility Antigens Class I / Q000032:analysis*; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000276:immunology*; D008297:Male; D012150:Polymorphism, Restriction Fragment Length; D011379:Prognosis; D011990:Receptors, Transferrin
D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D014408:Biomarkers, Tumor; C068126:CD71 antigen; D005819:Genetic Markers; D015395:Histocompatibility Antigens Class I; D011990:Receptors, Transferrin